The FDA cleared Apexian Pharmaceuticals Inc.'s IND for oncology candidate APX-3330 in three days, CEO Steve Carchedi told BioWorld, "which is probably a world record. It was, at that time, the most widely used unapproved drug," with safety data in no fewer than 422 patients already available.